this is spartan! apalutamide treatment for nmcrpc
Published 6 years ago • 870 plays • Length 3:40Download video MP4
Download video MP3
Similar videos
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
2:11
straightforward study design: spartan trial of apalutamide for nmcrpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
15:06
comparing real world evidence to phase iii data on apalutamide for nmcrpc
-
6:13
ep. 7: current treatment and imaging options for nmcrpc
-
1:22
how will the results of the spartan study impact us clinical practice in prostate cancer?
-
13:23
immune therapy for metastatic castration-resistant prostate cancer
-
6:38
apalutamide vs enzalutamide: insights on real-world survival benefits and clinical implications
-
4:59
does a dre or biopsy affect psa, does erleada affect psa | answering youtube comments #15 | pcri
-
1:19
nonmetastatic crpc: meeting an unmet need
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
3:19
live long and prosper: enzalutamide for nmcrpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc
-
35:31
m0 space and the spartan trial
-
1:20
panther: apalutamide abiraterone in black and white mcrpc patients
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
5:22
response to apa among patients with nmcrpc from spartan by decipher genomic classifier score
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
0:51
presto: the benefits of intensifying treatment in prostate cancer
-
5:18
spartan analysis finds molecular signatures that may predict response to apalutamide | felix feng
-
1:10
dr. gomella on the fda approval of apalutamide for nonmetastatic crpc